Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Merck presents positive results from phase 2b/3 trial of clesrovimab, an investigational RSV preventative monoclonal antibody at IDWeek 2024: Rahway, New Jersey Saturday, October ...

Interim findings show clesrovimab has a similar safety profile to palivizumab. Clesrovimab, an investigational respiratory syncytial virus (RSV) fusion glycoprotein neutralizing monoclonal ...

(RTTNews) - Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company's investigational prophylactic monoclonal ...

Merck & Co. on Thursday reported further positive results from a late-stage study of its proposed clesrovimab vaccine aimed at protecting infants from respiratory syncytial virus, or RSV ...